{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:02:46Z","timestamp":1784545366004,"version":"3.55.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Horizontal Project of West China Fourth Hospital, Sichuan University","award":["KY2024HX07-02"],"award-info":[{"award-number":["KY2024HX07-02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the expression patterns of ERG, PTEN, and c-Myc proteins in prostate adenocarcinoma; analyze the status of the MYC gene; and evaluate their correlations with clinicopathologic parameters and patient prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, 152 prostate adenocarcinoma cases were analyzed. Immunohistochemistry was performed for ERG, PTEN, and c-Myc protein expression. Fluorescence in situ hybridization was used to assess ERG rearrangement, MYC gene breakage, and amplification. Statistical analyses were conducted to evaluate associations between molecular markers and clinicopathologic variables, as well as their impact on survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The positive expression rates for ERG, PTEN, and c-Myc high expression (immunoreactive score\u2009\u22655) were 9.9%, 86.8%, and 50%, respectively. The detection rate of MYC gene amplification was 27.6%. Both c-Myc high expression and MYC gene amplification were significantly associated with the high-grade group (defined as Grade Group\u2009\u22653 and\/or with cribriform pattern), lymphovascular invasion, advanced T stage, metastasis, and poor prognosis, with gene amplification demonstrating higher prognostic specificity. ERG protein expression was significantly correlated with PTEN positivity, whereas no significant association was found between MYC gene amplification and ERG protein expression; only a nonsignificant mutually exclusive trend was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>c-Myc activation, particularly MYC gene amplification, is a key driver and specific biomarker for an aggressive phenotype and poor prognosis in prostate adenocarcinoma. Combined detection of ERG, PTEN, and c-Myc status contributes to refining risk stratification systems. The lack of significant association between MYC amplification and ERG expression suggests they may represent distinct oncogenic pathways, warranting further validation in large prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag059","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:17:11Z","timestamp":1777637831000},"source":"Crossref","is-referenced-by-count":0,"title":["MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases"],"prefix":"10.1093","volume":"165","author":[{"given":"Mei","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mianyang Central Hospital , Mianyang, Sichuan Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanfen","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026072006065384700_aqag059-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"2026072006065384700_aqag059-B2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026072006065384700_aqag059-B3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"2026072006065384700_aqag059-B4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"Mmwr Morb Mortal Wkly Rep"},{"key":"2026072006065384700_aqag059-B5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s43018-025-00907-4","article-title":"Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management","volume":"5","author":"Wang","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"2026072006065384700_aqag059-B6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"2026072006065384700_aqag059-B7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"2026072006065384700_aqag059-B8","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1007\/s13277-016-5116-9","article-title":"TMPRSS2: ERG fusion gene occurs less frequently in Chinese patients with prostate cancer","volume":"37","author":"Jiang","year":"2016","journal-title":"Tumour Biol"},{"key":"2026072006065384700_aqag059-B9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"2026072006065384700_aqag059-B10","doi-asserted-by":"crossref","first-page":"e84959","DOI":"10.1371\/journal.pone.0084959","article-title":"ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients","volume":"9","author":"Qi","year":"2014","journal-title":"PLoS One"},{"key":"2026072006065384700_aqag059-B11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026072006065384700_aqag059-B12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41588-024-01676-z","article-title":"MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch","volume":"56","author":"Jakobsen","year":"2024","journal-title":"Nat Genet"},{"key":"2026072006065384700_aqag059-B13","doi-asserted-by":"crossref","first-page":"a014217","DOI":"10.1101\/cshperspect.a014217","article-title":"MYC, metabolism, cell growth, and tumorigenesis","volume":"3","author":"Dang","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026072006065384700_aqag059-B14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/1947601910379132","article-title":"MYC and prostate cancer","volume":"1","author":"Koh","year":"2010","journal-title":"Genes Cancer"},{"key":"2026072006065384700_aqag059-B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/pcan.2010.31","article-title":"Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence","volume":"13","author":"Hawksworth","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026072006065384700_aqag059-B16","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"key":"2026072006065384700_aqag059-B17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/modpathol.2008.111","article-title":"Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis","volume":"21","author":"Gurel","year":"2008","journal-title":"Mod Pathol"},{"key":"2026072006065384700_aqag059-B18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fonc.2018.00377","article-title":"The role of immunohistochemical analysis as a tool for the diagnosis, prognostic evaluation and treatment of prostate cancer: a systematic review of the literature","volume":"8","author":"Carneiro","year":"2018","journal-title":"Front Oncol"},{"key":"2026072006065384700_aqag059-B19","doi-asserted-by":"crossref","first-page":"153851","DOI":"10.1016\/j.prp.2022.153851","article-title":"Molecular landscape of c-Myc signaling in prostate cancer: a roadmap to clinical translation","volume":"233","author":"Faskhoudi","year":"2022","journal-title":"Pathol Res Pract"},{"key":"2026072006065384700_aqag059-B20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc2402","article-title":"Recurrent gene fusions in prostate cancer","volume":"8","author":"Kumar-Sinha","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2026072006065384700_aqag059-B21","doi-asserted-by":"crossref","first-page":"11769351211027592","DOI":"10.1177\/11769351211027592","article-title":"Re-evaluate fusion genes in prostate cancer","volume":"20","author":"Wei","year":"2021","journal-title":"Cancer Inform"},{"key":"2026072006065384700_aqag059-B22","first-page":"524","article-title":"Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization","volume":"57","author":"Jenkins","year":"1997","journal-title":"Cancer Res"},{"issue":"15","key":"2026072006065384700_aqag059-B23","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/cncr.26729","article-title":"Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy","volume":"118","author":"Zafarana","year":"2012","journal-title":"Cancer"},{"key":"2026072006065384700_aqag059-B24","doi-asserted-by":"crossref","first-page":"106.e17","DOI":"10.1016\/j.urolonc.2022.10.002","article-title":"Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis","volume":"41","author":"Alshalalfa","year":"2023","journal-title":"Urol Oncol"},{"key":"2026072006065384700_aqag059-B25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/genes8060151","article-title":"MYC deregulation in primary human cancers","volume":"8","author":"Kalkat","year":"2017","journal-title":"Genes (Basel)"},{"key":"2026072006065384700_aqag059-B26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41586-022-05154-6","article-title":"African-specific molecular taxonomy of prostate cancer","volume":"609","author":"Jaratlerdsiri","year":"2022","journal-title":"Nature"},{"key":"2026072006065384700_aqag059-B27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"2026072006065384700_aqag059-B28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"2026072006065384700_aqag059-B29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41585-022-00622-0","article-title":"Race and prostate cancer: genomic landscape","volume":"19","author":"Arenas-Gallo","year":"2022","journal-title":"Nat Rev Urol"},{"key":"2026072006065384700_aqag059-B30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s43042-020-00092-2","article-title":"Detection of tmprss2-erg and tmprss2-egr1 gene fusion in prostate cancer from a Chinese population","volume":"21","author":"Xu","year":"2020","journal-title":"Egypt J Med Hum Genet"},{"key":"2026072006065384700_aqag059-B31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/modpathol.2010.149","article-title":"ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples","volume":"23","author":"Miyagi","year":"2010","journal-title":"Modern Pathol"},{"key":"2026072006065384700_aqag059-B32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"2026072006065384700_aqag059-B33","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.7150\/jca.30025","article-title":"ERG tumor type is less frequent in high grade and high stage prostate cancers of Chinese men","volume":"10","author":"Baohong","year":"2019","journal-title":"J Cancer"},{"key":"2026072006065384700_aqag059-B34","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-19-4112","article-title":"Genomic profiling of prostate cancers from men with African and European ancestry","volume":"26","author":"Koga","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026072006065384700_aqag059-B35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.17116\/patol20248603130","article-title":"Amplification of the c-MYC gene in acinar prostate adenocarcinoma. Morphogenic comparisons","volume":"86","author":"Khorzhevskii","year":"2024","journal-title":"Arkh Patol"},{"key":"2026072006065384700_aqag059-B36","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.humpath.2014.02.011","article-title":"Biological correlates of prostate cancer perineural invasion diameter","volume":"45","author":"Olar","year":"2014","journal-title":"Hum Pathol"},{"key":"2026072006065384700_aqag059-B37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41391-021-00486-2","article-title":"Clinicogenomic characterization of prostate cancer liver metastases","volume":"25","author":"Alshalalfa","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026072006065384700_aqag059-B38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/jcm13030734","article-title":"Prostate cancer liver metastasis: an ominous metastatic site in need of distinct management strategies","volume":"13","author":"Shiner","year":"2024","journal-title":"J Clin Med"},{"key":"2026072006065384700_aqag059-B39","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.clgc.2023.10.008","article-title":"The molecular, immunologic, and clinicodemographic landscape of MYC-amplified advanced prostate cancer","volume":"22","author":"Jin","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026072006065384700_aqag059-B40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41416-023-02485-7","article-title":"Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility","volume":"130","author":"O\u2019Malley","year":"2024","journal-title":"Br J Cancer"},{"key":"2026072006065384700_aqag059-B41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2013.00240","article-title":"Genomic rearrangements of PTEN in prostate cancer","volume":"3","author":"Phin","year":"2013","journal-title":"Front Oncol"},{"key":"2026072006065384700_aqag059-B42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12094-019-02170-3","article-title":"The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis","volume":"22","author":"Liu","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2026072006065384700_aqag059-B43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-14-3280","article-title":"Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer","volume":"76","author":"Hubbard","year":"2016","journal-title":"Cancer Res"},{"key":"2026072006065384700_aqag059-B44","doi-asserted-by":"crossref","first-page":"e17449","DOI":"10.1371\/journal.pone.0017449","article-title":"MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors","volume":"6","author":"Clegg","year":"2011","journal-title":"PLoS One"},{"key":"2026072006065384700_aqag059-B45","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1038\/s41467-024-51450-2","article-title":"Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer","volume":"15","author":"Graham","year":"2024","journal-title":"Nat Commun"},{"key":"2026072006065384700_aqag059-B46","doi-asserted-by":"crossref","first-page":"113221","DOI":"10.1016\/j.celrep.2023.113221","article-title":"MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer","volume":"42","author":"Crowell","year":"2023","journal-title":"Cell Rep"},{"key":"2026072006065384700_aqag059-B47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41585-022-00649-3","article-title":"The endoplasmic reticulum stress response in prostate cancer","volume":"19","author":"de la Calle","year":"2022","journal-title":"Nat Rev Urol"},{"key":"2026072006065384700_aqag059-B48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/modpathol.3880487","article-title":"Loss of p53 and c-myc overrepresentation in stage T2-3N1-3M0 prostate cancer are potential markers for cancer progression","volume":"15","author":"Qian","year":"2002","journal-title":"Modern Pathol"},{"key":"2026072006065384700_aqag059-B49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00428-014-1540-7","article-title":"Prognostic prostate tissue biomarkers of potential clinical use","volume":"464","author":"Van der Kwast","year":"2014","journal-title":"Virchows Arch"},{"key":"2026072006065384700_aqag059-B50","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3390\/cancers13102363","article-title":"Copy number profiles of prostate cancer in men of Middle Eastern ancestry","volume":"13","author":"Albawardi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026072006065384700_aqag059-B51","doi-asserted-by":"crossref","first-page":"101679","DOI":"10.1016\/j.xcrm.2024.101679","article-title":"Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction","volume":"5","author":"Sun","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026072006065384700_aqag059-B52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/aja.aja_36_19","article-title":"Integrative molecular characterization of Chinese prostate cancer specimens","volume":"22","author":"Lv","year":"2020","journal-title":"Asian J Androl"},{"key":"2026072006065384700_aqag059-B53","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11523-025-01169-x","article-title":"MYC as a target for cancer treatment: from undruggable to druggable?","volume":"20","author":"Duffy","year":"2025","journal-title":"Target Oncol"},{"key":"2026072006065384700_aqag059-B54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/genes8020071","article-title":"Therapeutic approaches targeting MYC-driven prostate cancer","volume":"8","author":"Rebello","year":"2017","journal-title":"Genes (Basel)"},{"key":"2026072006065384700_aqag059-B55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/genes15040450","article-title":"Transcription factors in prostate cancer: insights for disease development and diagnostic and therapeutic approaches","volume":"15","author":"Silva","year":"2024","journal-title":"Genes (Basel)"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/6\/aqag059\/68543573\/aqag059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/6\/aqag059\/68543573\/aqag059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:07:09Z","timestamp":1784542029000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag059\/8710063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag059","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"aqag059"}}